Drug Profile


Alternative Names: TGFK08AA; TGFK08AA-ER; TGFK08AA-IR

Latest Information Update: 08 Jan 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Developer Fabre-Kramer Pharmaceuticals
  • Class
  • Mechanism of Action Serotonin 1A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Generalised anxiety disorder

Most Recent Events

  • 08 Jan 2016 Phase-II development for Generalised anxiety disorder is ongoing in USA (PO, controlled release)
  • 15 Jul 2010 Phase-II clinical trials in Generalised anxiety disorder in USA prior to July 2010 (PO, controlled-release & PO, immediate-release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top